BRISTOL MYERS SQUIBB

🇫🇷France

Country: 🇫🇷France

Ownership: -

Established: 1989-01-01

Employees: 30K

Market Cap: $97.5B

Website: https://www.bms.com/

Clinical Trials

A Study of MDX-1106 to Treat Patients With Hepatitis C Infection

Phase 1

Completed

Conditions: Hepatitis C

Interventions: Drug: MDX1106-02
Drug: Placebo

First Posted Date: 2008-06-23

Last Posted Date: 2010-04-23

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 54

Registration Number: NCT00703469

Locations: 🇺🇸
Advanced Clinical Resesarch Institute, Anaheim, California, United States
🇺🇸
Quest Clinical Research, San Francisco, California, United States
🇺🇸
Springfield Clinic Infectious Diseases, Springfield, Illinois, United States

and more 4 locations

Proof of Confidence Study of CCR2 Antagonist (BMS-741672) in Insulin Resistance

Phase 2

Completed

Conditions: Type 2 Diabetes

Interventions: Drug: CCR2 Antagonist
Drug: Placebo

First Posted Date: 2008-06-18

Last Posted Date: 2015-10-12

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 58

Registration Number: NCT00699790

Locations: 🇷🇺
Local Institution, Yaroslavl, Russian Federation

Randomized Phase II Trial of Letrozole With or Without Dasatinib as First and Second-line Treatment for Hormone Receptor-positive, HER2-negative Post-menopausal Breast Cancer That is Unresectable, Locally Recurrent or Metastatic

Phase 2

Completed

Conditions: Metastatic Breast Cancer

Interventions: Drug: Dasatinib
Drug: Letrozole

First Posted Date: 2008-06-12

Last Posted Date: 2016-06-13

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 120

Registration Number: NCT00696072

Locations: 🇺🇸
Florida Cancer Institute - New Hope, Hudson, Florida, United States
🇺🇸
Arizona Oncology Associates D.B.A. Hematology Oncology, Tucson, Arizona, United States
🇺🇸
Central Indiana Cancer Centers, Carmel, Indiana, United States

and more 20 locations

BMS-741672 for Diabetic Neuropathic Pain

Phase 2

Completed

Conditions: Neuropathic Pain

Interventions: Drug: BMS-741672
Drug: Placebo

First Posted Date: 2008-05-23

Last Posted Date: 2015-10-12

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 50

Registration Number: NCT00683423

Locations: 🇺🇸
University Clinical Investigators, Inc., Tustin, California, United States
🇺🇸
Palm Beach Neurological Center, Palm Beach Gardens, Florida, United States
🇺🇸
Research Institute Of Dallas, P.A., Dallas, Texas, United States

and more 5 locations

An Open-Label Treatment Protocol to Provide Metreleptin for the Treatment of Diabetes Mellitus and/or Hypertriglyceridemia Associated With Lipodystrophy

Not Applicable

Completed

Conditions: Lipodystrophy

Interventions: Drug: metreleptin

First Posted Date: 2008-05-14

Last Posted Date: 2015-04-30

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 41

Registration Number: NCT00677313

Locations: 🇺🇸
Research Site, Greenville, North Carolina, United States
🇺🇸
Local Institution, Reno, Nevada, United States

A Phase 1 Study of BMS-833923 (XL139) in Subjects With Advanced or Metastatic Cancer

Phase 1

Completed

Conditions: Hedgehog Pathway
Smoothened
Basal Cell Carcinoma (BCC)
Basal Cell Nevoid Syndrome (BCNS)

Interventions: Drug: BMS-833923 (XL139)

First Posted Date: 2008-05-01

Last Posted Date: 2014-08-15

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 53

Registration Number: NCT00670189

Locations: 🇺🇸
Mayo Clinic Rochester, Rochester, Minnesota, United States
🇺🇸
Southwest Texas Addiction Research And Tech (Start) Center, San Antonio, Texas, United States
🇨🇦
Local Institution, Toronto, Ontario, Canada

A Single Ascending Dose Study of BMS-791325 in HCV Infected Subjects

Phase 1

Completed

Conditions: Chronic Hepatitis C

Interventions: Drug: BMS-791325
Drug: Placebo

First Posted Date: 2008-04-23

Last Posted Date: 2015-10-09

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 24

Registration Number: NCT00664625

Locations: 🇺🇸
Washington University School Of Medicine, St. Louis, Missouri, United States
🇺🇸
University Of Pennsylvania, Philadelphia, Pennsylvania, United States
🇦🇷
Local Institution, Buenos Aires, Argentina

and more 3 locations

A Multiple Ascending Dose Study of Daclatasvir (BMS-790052) in Hepatitis C Virus Genotype 1 Infected Subjects

Phase 2

Completed

Conditions: Chronic Hepatitis C

Interventions: Drug: Daclatasvir
Drug: Placebo

First Posted Date: 2008-04-22

Last Posted Date: 2015-10-14

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 167

Registration Number: NCT00663208

Locations: 🇺🇸
West Coast Clinical Trials, Llc, Cypress, California, United States
🇵🇷
Local Institution, Santurce, Puerto Rico
🇺🇸
Advanced Clinical Res Inst, Anaheim, California, United States

and more 5 locations

Phase IIIB Switching From Intravenous to Subcutaneous Study

Phase 3

Completed

Conditions: Arthritis, Rheumatoid

Interventions: Drug: Abatacept

First Posted Date: 2008-04-22

Last Posted Date: 2015-03-09

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 123

Registration Number: NCT00663702

Locations: 🇺🇸
Rheumatology Associates Of N. Al, P.C., Huntsville, Alabama, United States
🇺🇸
Desert Medical Advances, Palm Desert, California, United States
🇺🇸
Valerius Medical Group &Research Ctr. Of Greater Long Beach, Long Beach, California, United States

and more 16 locations

A Study of MDX-1100 in Subjects With Active Ulcerative Colitis

Phase 2

Completed

Conditions: Ulcerative Colitis

Interventions: Biological: MDX-1100
Biological: sterile saline for injection

First Posted Date: 2008-04-11

Last Posted Date: 2015-10-12

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 110

Registration Number: NCT00656890

Locations: 🇺🇸
Washington University School of Medicine, St. Louis, Missouri, United States
🇺🇸
Florida Medical Clinic-Tampa Clinic, Tampa, Florida, United States
🇺🇸
Chevy Chase Clinical Research, Chevy Chase, Maryland, United States

and more 4 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy